Pulmocide's Series B Round

Pulmocide raised a round of funding on March 20, 2017.

Pulmocide is a biotechnology firm developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by RSV and Aspergillus.…

Articles about Pulmocide's Series B Round: